Insider Selling: Zynex, Inc. (NASDAQ:ZYXI) CEO Sells 2,000 Shares of Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of Zynex stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $8.63, for a total value of $17,260.00. Following the sale, the chief executive officer now directly owns 14,621,350 shares in the company, valued at $126,182,250.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Thomas Sandgaard also recently made the following trade(s):

• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.92, for a total value of $17,840.00.

Zynex Price Performance

Zynex stock opened at $8.76 on Monday. The stock’s 50 day moving average is $8.11 and its 200 day moving average is $9.04. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15. The firm has a market cap of $278.97 million, a P/E ratio of 58.40 and a beta of 0.53. Zynex, Inc. has a one year low of $7.15 and a one year high of $13.77.

Zynex (NASDAQ:ZYXI) last issued its quarterly earnings results on Thursday, October 24th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.01. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The firm had revenue of $49.97 million for the quarter, compared to analyst estimates of $50.83 million. During the same period in the previous year, the firm earned $0.10 earnings per share. The company’s revenue was up .1% compared to the same quarter last year. As a group, research analysts expect that Zynex, Inc. will post 0.2 EPS for the current year.

Hedge Funds Weigh In On Zynex

Several institutional investors have recently added to or reduced their stakes in ZYXI. Investment Partners Asset Management Inc. acquired a new position in Zynex in the third quarter valued at approximately $96,000. Hsbc Holdings PLC acquired a new position in Zynex in the second quarter valued at approximately $113,000. Quest Partners LLC lifted its stake in Zynex by 646.7% in the second quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock valued at $120,000 after buying an additional 11,195 shares during the period. State Board of Administration of Florida Retirement System acquired a new position in Zynex in the first quarter valued at approximately $137,000. Finally, Principal Financial Group Inc. lifted its stake in Zynex by 10.4% in the second quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock valued at $182,000 after buying an additional 1,846 shares during the period. 29.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ZYXI shares. HC Wainwright lifted their price objective on Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Royal Bank of Canada cut their price objective on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.